Home

Protagonist Therapeutics, Inc. (PTGX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Protagonist Therapeutics, Inc. (PTGX)

Go deeper and ask any question about PTGX

Company Performance

Current Price

as of Oct 03, 2024

$44.34

P/E Ratio

16.88

Market Cap

$2.61B

Description

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Metrics

Overview

  • HQNewark, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerPTGX
  • Price$44.34-1.42%

Trading Information

  • Market Cap$2.61B
  • Float94.48%
  • Average Daily Volume (1m)742,103
  • Average Daily Volume (3m)690,479
  • EPS$2.78

Company

  • Revenue$319.12M
  • Rev Growth (1yr)N/A
  • Net Income-$30.62M
  • Gross Margin78.59%
  • EBITDA Margin-909.55%
  • EBITDA-$37.90M
  • EV$1.57B
  • EV/Revenue4.92
  • P/E16.88
  • P/S8.52
Documents
SEC Filings
8-K (2024-09-20)
8-K (2024-08-06)
8-K (2024-06-26)
8-K (2024-05-07)
8-K (2024-02-27)
8-K (2024-01-31)
8-K (2024-01-16)
8-K (2024-01-08)
8-K (2023-11-02)
8-K (2023-10-30)
8-K (2023-08-03)
8-K (2023-07-05)
8-K (2023-07-03)
8-K (2023-05-30)
8-K (2023-05-04)
8-K (2023-04-10)
8-K (2023-03-15)
8-K (2023-03-10)
8-K (2023-01-06)
10-Q (2024-08-06)
10-Q (2024-05-07)
10-Q (2023-11-02)
10-Q (2023-08-03)
10-Q (2023-05-04)
10-K (2024-02-27)
10-K (2023-03-15)
Earnings Calls
Earnings Report 2020Q4
Earnings Report (2021-03-10)
Factset Street Account
Protagonist Therapeutics reports Q3 EPS ($0.58) vs FactSet ($0.69) [6 est, ($0.76)-(0.67)] ($15.41, 0.00) (2023-11-03T18:16:47Z)
Protagonist Therapeutics initiated overweight at Capital One Securities ($14.08, 0.00) (2023-10-30T10:34:03Z)
Protagonist Therapeutics holder Point72 discloses 5.5% passive stake - 13G ($20.73, 0.00) (2023-12-18T21:20:36Z)
Protagonist Therapeutics announces advancement of JNJ-2113 across multiple indications ($16.24, 0.00) (2023-10-09T11:04:14Z)
Protagonist Therapeutics acheives $50M milestone after third patient dosed in phase 3 study of JNJ-2113 in moderate-to-severe psoriasis ($15.11, 0.00) (2023-11-01T20:43:31Z)
Protagonist announces two new phase 3 ICONIC studies in psoriasis evaluating JNJ-2113 in head-to-head comparisons with deucravacitinib ($17.23, 0.00) (2023-11-27T14:09:07Z)